1797.HK
Livestreaming e-commerce platform East Buy Holding on Wednesday reported its interim net profit for the six months through last November narrowed by 57.4% year-on-year to 249 million yuan.

The latest: Livestreaming e-commerce platform East Buy Holding Ltd. (1797.HK) on Wednesday reported its net profit for the six months through last November fell by 57.4% year-on-year to 249 million yuan ($35.2 million), according to an announcement issued on Wednesday.

Looking up: The company’s revenue rose by 34.4% to 2.8 billion yuan, after it implemented a series of new initiatives to boost its private label products and upgrade its services.

Take Note: The company’s selling, marketing and administrative expenses more than doubled for the period, causing its profit before tax to drop by 49.9% to 378 million yuan.

Digging Deeper: Since ceasing its K-12 online tutoring business last year following a government crackdown, East Buy has transformed into a livestream e-commerce platform. To more clearly delineate its business lines, the company sold its residual tutoring operations to its education-focused parent, New Oriental (EDU.US; 9901.HK), and has focused on selling private-label products and livestreaming. The company’s average daily gross merchandise value (GMV), average daily volume of viewers and comprehensive conversion showed signs of decline last year, prompting it to try to move away from its reliance on short video app Douyu and shift to the Taobao e-commerce marketplace and live broadcasts on its own app.

Market Reaction: East Buy shares plunged on Thursday to close down 11.9% at HK$23.25 by the midday break. They now trade at the lower end of their 52-week range

Translation by A. Au

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Should Daqo privatize?

Now all grown up, should Daqo consider privatizing?

The polysilicon maker has more than enough cash to purchase all of its outstanding shares, as its stock remains stubbornly undervalued by investors Key Takeaways: Daqo’s output rose 80% in…
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs.

Profit setback for Simcere Pharma in novel drugs quest

The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…